Filter Results
Filter Results
Integrated Biologics (16) Specialized Modalities (13) Advanced Synthesis (10) Capsules & Health Ingredients (5) Corporate (3)
Media Advisory (47) New Technologies (13) Partnerships (10) Sustainability (3) New Products (2) General (1)
2025 (9) 2024 (21) 2023 (16) 2022 (1)
English (47)
EnglishX
Reset Filters
   Loading...
Showing 41‐47 of 47
Media Advisory
13 Feb 2023
Lonza to Expand Early Development Services Offering into North America
A new facility in Cambridge, Massachusetts (US) will open in May 2023, making Lonza’s Early Development Services easily accessible to US-based customers New laboratories will...
Media Advisory
31 Jan 2023
Lonza Celebrates Groundbreaking of New Commercial Drug Product Facility in Stein
Milestone for the development of Lonza’s first large-scale drug product manufacturing facility based in Stein (CH) The facility will complete Lonza’s strategic commitment to...
Media Advisory
30 Jan 2023
Lonza Expands Manufacturing Collaboration With Asher Biotherapeutics to Include AB248, a Cis-Targeted IL-2 Immunotherapy
Asher Bio’s lead drug candidate AB248, a cis-targeted IL-2 immunotherapy for the treatment of cancer, to be manufactured at Lonza’s site in Visp (CH) Agreement builds upon...
Media Advisory
17 Jan 2023
Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering
Cristal Therapeutic CliCr® technology and McSAF Inside® technology will be integrated into the Lonza Bioconjugation Toolbox Collaborations further the development of an...
Media Advisory
16 Jan 2023
Lonza Completes Expansion to Solid Form Services Facility at Bend (US) Site
The offering complements Lonza’s API development services and first-in-human services, aimed at the rapid advancement of small molecules New facility is based at Lonza’s Bend,...
Media Advisory
09 Jan 2023
Lonza and Context Therapeutics Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being...
Media Advisory
25 Oct 2022
Lonza Expands Global Process Development Team and Laboratory Spaces for Cell and Gene Development
Lonza to almost double the size of the Cell and Gene Therapy Development laboratories at its Houston facility, adding an extra 15,000 square feet of laboratory space
< 1 2 3